Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety DisordersGlobeNewsWire • 06/23/22
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth InvitationalGlobeNewsWire • 06/17/22
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access EventGlobeNewsWire • 06/02/22
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety DisordersGlobeNewsWire • 05/24/22
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business UpdateGlobeNewsWire • 05/12/22
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business UpdateGlobeNewsWire • 03/10/22
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder StudiesBenzinga • 02/08/22
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)GlobeNewsWire • 02/08/22
Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)Accesswire • 12/10/21